Agenus is trying to bring a new immune-based approach to colorectal cancer where current options often fall short, and early trial results suggest it could help some hard-to-treat patients. The big question is whether the company can turn that early promise into approvals fast enough to avoid long, expensive trials and ongoing cash strain.Read more
Agenus is trying to bring new immune-based cancer treatments to market, but tougher regulators and long, expensive late-stage trials may keep pushing approvals further out. With cash needs staying high and bigger rivals moving fast, the key question is whether its most promising drug combo can break through before funding and delays take their toll.Read more
Key Takeaways Strategic partnerships and early leadership in cold tumor therapies position Agenus for sustained R&D, accelerated cash inflow, and robust long-term revenue growth. Rapid trial enrollment, label expansion potential, and diversification into cell therapy enable faster product launches, earnings realization, and durable, high-margin revenue streams.Read more
No trending discussion available.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
